CatalystFDA/Bio

OSE Immunotherapeutics Welcomes First Patient Dosed by Veloxis in the Phase 2 RENGEVITY-201 Trial Evaluating Pegrizeprument (VEL-101) for the Prevention of Organ Rejection in Kidney Transplant Recipie

First patient dosed in Phase 2 trial for kidney transplant rejection prevention.

What changed

First patient dosed in Phase 2 trial for kidney transplant rejection prevention.

Why it matters

First patient dosed in Phase 2 trial for kidney transplant rejection prevention. — impact context not separately stored; see What changed.

Sources